Related Experiment Video
Updated: Apr 26, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
Published on: January 24, 2017
Making a therapeutic choice: human versus recombinant fractions - can we do it?
1Mt. Sinai Medical Center, New York, NY 10029, USA. louis.aledort@mountsinai.org
Abstract:
New manufacturing methods have resulted in production of higher purity human-derived products and recombinant factors with less human- or animal-derived reagents or stabilizers for the treatment of congenital coagulation disorders. In addition, new viral inactivation processes are being used to reduce the chance of viral contamination. Preferred treatment approaches are moving toward using newer-generation agents. At the same time, rationale exists for continuing fractionation of all types of products, based on considerations including cost, product availability, safety issues, and specific clinical situations for which a recombinant or high-purity product is not available. These issues and others are reviewed in the context of making a therapeutic choice.
Related Concept Videos
Recombinant DNA
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Central Dogma
RNA is the Missing Link Between DNA and Proteins
In the early 1900s, scientists discovered that DNA stores all the information needed for cellular functions and that proteins perform most of these functions. However, the mechanisms of converting genetic information into functional proteins remained unknown for many years. Initially, it was believed that a single gene is...
Drug Products: Biologics, Biosimilars and Interchangeables
Upstream Processing
Production of Pharmaceuticals

